Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-05-01
2007-05-01
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069700, C424S192100, C424S204100
Reexamination Certificate
active
10871138
ABSTRACT:
Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.
REFERENCES:
patent: 4666847 (1987-05-01), Alford et al.
patent: 4716038 (1987-12-01), Stanford et al.
patent: 4724144 (1988-02-01), Rook et al.
patent: 4734362 (1988-03-01), Hung et al.
patent: 4784941 (1988-11-01), Watanabe et al.
patent: 4797359 (1989-01-01), Finkelstein et al.
patent: 4918164 (1990-04-01), Hellstrom et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5114844 (1992-05-01), Cohen et al.
patent: 5204259 (1993-04-01), Helting et al.
patent: 5256767 (1993-10-01), Salk et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5504005 (1996-04-01), Bloom et al.
patent: 5578300 (1996-11-01), Schmidt et al.
patent: 5580563 (1996-12-01), Tam
patent: 5599545 (1997-02-01), Stanford et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5858368 (1999-01-01), Smith et al.
patent: 5925362 (1999-07-01), Spitler et al.
patent: 5935576 (1999-08-01), Srivastava
patent: 5948646 (1999-09-01), Srivastava
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6007806 (1999-12-01), Lathe et al.
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 6017540 (2000-01-01), Srivastava et al.
patent: 6017544 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6130087 (2000-10-01), Srivastava et al.
patent: 6136315 (2000-10-01), Srivastava
patent: 6139841 (2000-10-01), Srivastava
patent: 6143299 (2000-11-01), Srivastava
patent: 6156302 (2000-12-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava
patent: 6187312 (2001-02-01), Srivastava
patent: 6322790 (2001-11-01), Srivastava
patent: 6335183 (2002-01-01), Young et al.
patent: 6338952 (2002-01-01), Young et al.
patent: 6380157 (2002-04-01), Jarrett et al.
patent: 6495347 (2002-12-01), Siegel et al.
patent: 6497880 (2002-12-01), Wisniewski
patent: 6524825 (2003-02-01), Mizzen et al.
patent: 1248631 (2000-03-01), None
patent: 0 118 393 (1984-09-01), None
patent: 0 230 222 (1987-09-01), None
patent: 0 262 710 (1988-04-01), None
patent: 0 322 990 (1989-07-01), None
patent: 0 521 220 (1993-01-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO 85/05034 (1985-11-01), None
patent: WO 88/00974 (1988-02-01), None
patent: WO 88/05823 (1988-08-01), None
patent: WO 88/06591 (1988-09-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO90/10230 (1990-09-01), None
patent: WO 90/15873 (1990-12-01), None
patent: WO 91/02542 (1991-03-01), None
patent: WO 91/15572 (1991-10-01), None
patent: WO 92/08484 (1992-05-01), None
patent: WO 92/08488 (1992-05-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 95/31994 (1995-11-01), None
patent: WO 96/10421 (1996-04-01), None
patent: WO 96/19496 (1996-06-01), None
patent: WO 96/26277 (1996-08-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/04706 (1998-02-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 98/35705 (1998-08-01), None
patent: WO 99/07860 (1999-02-01), None
patent: WO 99/33868 (1999-07-01), None
patent: WO 00/19828 (2000-04-01), None
patent: WO 00/23093 (2000-04-01), None
patent: WO 01/04344 (2001-01-01), None
patent: WO 01/17554 (2001-03-01), None
patent: WO 01/52877 (2001-07-01), None
patent: WO 01/52890 (2001-07-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/52791 (2006-07-01), None
Agranovsky et al., “Putative 65 kDa Protein of Beet Yellows Closterovirus Is a Homologue of HSP70 Heat Shock Proteins,” J. Mol. Biol., 217:603-610 (1991).
Anthony et al., “Priming of CD8+CTL Effector Cells In Mice By Immunization With a Stress Protein-Influenza Virus Nucleoprotein Fusion Molecule”, Vaccine, 17:373-383 (1999).
Ardeshir et al., “A 75 Kd Merozoite Surface Protein of Plasmodium Falciparum which is Related to the 70 kd Heat-Shcok Proteins,” EMBO J., 6(2):493-499 (1987).
Arnosti et al., “Characterization of heat shock inBacillus subtilis,” J. BACT., 168(3):1243-1249 (Dec. 1986).
Arrigo and Welch, “Characterization and Purification of the Small 28,000-Dalton Mammalian Heat Shock Protein”, J. Biol. Chem., 262(32):15359-15369 (1987).
Barrios et al., “Heat shock proteins as carrier molecules: in vivo helper effect mediated byEscherichia coliGroEL and DnaK proteins requires cross-linking with antigen,” Clin. Exp. Immunol., 98:229-233 (1994).
Barrios et al., “Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming,” Eur. J. Immunol., 22:1365-1372 (1992).
Beech et al., “CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis,” J. Immunol. 159:3692-3697 (1997).
Bennett et al., “Help for Cytotoxic-T-cell Responses is Mediated by CD40 Signalling,” Nature 393:478-480 (Jun. 4, 1998).
Bertelli et al., “BCG-Induced Resistance inTrypanosoma cruziExperimental Infections,” Tropenmed Parasitol, 32:93-96 (1981).
Birk et al., “T-cell autoimmunity in type 1 diabetes mellitus,” Curr. Opin. Immunol., 5:903-909 (1993).
Blachere et al., “Heat Shock Protein-Peptide Complexes, Reconstituted in Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity,” J. Exp. Med. 186(8): 1315-1322 (Oct. 20, 1997).
Blander and Horwitz, “Major Cytoplasmic Membrane Protein of Legionella Pneumophila, a Genus Common Antigen and Member of the hsp 60 Family of Heat Shock Proteins, Induces Protective Immunity in a Guinea Pig Model of Legionnaires' Disease,” J. Clin. Invest., 91:717-723 (1993).
Borysiewicz et al, “A recombinant vaccinia virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,” Lancet, 347:1523-27 (1996).
Breloer et al., “In Vivo and In Vitro Activation of T Cells After Administration of Ag-Negative Heat Shock Proteins,” J. Of Immun. 162:3141-3147 (1999).
Butini et al., “Comparative Analysis of HIV-specific CTL Activity in Lymphoid Tissue and Peripheral Blood,” J. Cell Biochem. Suppl. 18B Abstract J306 (1994).
Cain and Howett, “Preventing cervical cancer,” Science, 288:1753-54 (2000).
Cassell et al., “A Phase II Study on the Postsurgical Management of Stage Malignant Melanoma With a Newcastle Disease Virus Oncolysate,” Cancer, 52:856-860 (Sep. 1983).
Cassell et al., “Viral Oncolysate in the Management of Malignant Melanoma, I. Preparation of the Oncolysate and Measurement of Immunologic Responses” Cancer, 40: 672-679 (Aug. 1977).
Catelli et al., “The common 90-kb protein component of non-transformed ′8S′ steroid receptors is a heat-shock protein”, EMBO J., 4(12):3131-3135 (1985).
Chandrasekhar et al., “Purification and Properties of the groES Morphogenetic Protein ofEscherichia coli”, J. Biol. Chem., 261(26):12414-12419 (1986).
Che
Boux Leslie J.
Goldstone Stephen E.
Neefe John R.
Siegel Marvin
Winnett Mark T.
Nventa Biopharmaceuticals Corporation
Salimi Ali R.
LandOfFree
Human papilloma virus treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human papilloma virus treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human papilloma virus treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3792415